Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
about
The effects of idarubicin versus other anthracyclines for induction therapy of patients with newly diagnosed leukaemiaReduced-intensity conditioning allogeneic hematopoietic-cell transplantation for older patients with acute myeloid leukemiaVolasertib for AML: clinical use and patient considerationInfections in myelodysplastic syndromesPost-remission therapy for acute myeloid leukemiaAcute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management.Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Epigenetic therapies in MDS and AMLAzacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia.Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells.Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control studyMeta-analysis of randomised clinical trials comparing idarubicin + cytarabine with daunorubicin + cytarabine as the induction chemotherapy in patients with newly diagnosed acute myeloid leukaemiaImpact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteriaPhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.Retrospective comparison of fludarabine in combination with intermediate-dose cytarabine versus high-dose cytarabine as consolidation therapies for acute myeloid leukemia.Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsTreatment of acute myeloid leukemia with 20-30% bone marrow blasts.Treating octogenarian and nonagenarian acute myeloid leukemia patients--predictive prognostic modelsClinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation.What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)?Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classificationLaromustine (cloretazine).Older patients with acute myeloid leukemia.Acute myeloid leukaemia in the elderly: a review.Acute myeloid leukemia in older adults.Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensusAcute myeloid leukemia in the elderly: do we know who should be treated and how?Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Management of Relapsed/Refractory Acute Myeloid Leukemia in the Elderly: Current Strategies and Developments.The safety of treatment options for elderly people with acute myeloid leukemia.Frontline treatment of acute myeloid leukemia in adults.Acute Myeloid Leukemia in the Elderly Patient: New StrategiesGuidelines on the treatment of acute myeloid leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2015.
P2860
Q24187297-37FA32D2-86D4-4EA7-ADA0-669A8B39BE76Q26744283-7484DDC9-86E0-4E2F-8BA4-5E98DFBB6E64Q26801131-9A06D9D6-ABBA-4D71-A911-9F4DAC5F3144Q26859275-F7AB840E-A9C2-400C-8C9E-38C74522BE08Q26995867-473E9071-D04A-4ED1-8639-8977C4A6B56DQ27851694-05DA3BE7-4A7A-4D35-A387-AE35D9EAE266Q30399209-9A980B3B-36FA-4640-9A70-2CF493808728Q33412609-CE50D927-5898-43AD-B708-24CDCA8E5019Q33423753-3410A8CC-3C3C-4669-A74B-6D0748E07B2FQ33574178-B5BF623D-AA4B-4082-8B53-1E17ED738926Q33859061-1E12BB77-F635-4A8D-B8F5-EA53C28BEB1BQ33863567-CFED45D0-CE94-466B-99C5-16218C6B78D3Q34172912-A3368C2D-A6C6-440F-8CD1-661B26E62549Q34421127-FED134CE-D7EC-46C6-A324-DC5CB180DC0EQ34543097-D88A314F-3192-40EE-9E8B-6ECC462D1CB6Q34673820-69CF8B10-9FE0-4024-80BC-2B6939C7EB40Q35018521-7AED0647-3B39-41E5-AEBB-D7CA95948C52Q35224437-12CF2647-9250-450C-BE6C-D3C357E12BEBQ36152664-6A853371-E283-49F5-98B0-E0F2F0F228DDQ36804633-35F21603-44EE-4170-BBAB-42260F4EBA86Q36934199-58D36803-AAF2-44D7-AE6A-79961A50AAF0Q37208349-0B333492-4CB3-4C78-9E0A-F0E00A4B7515Q37323006-42D72E01-8520-4D87-B93E-0EBEB459527DQ37337422-7734298A-A079-43FA-BA74-6FE19F0C0048Q37552031-0A2914F0-B204-4ED6-8CA8-860FBC90F97BQ37693943-D7DB93CA-562B-4017-AC5A-509D115BCC48Q37810969-2A068383-1E7A-4209-8161-ADDA56B6DC43Q37840260-30E409E7-7674-4247-9CAA-9F14E6722B3AQ38026008-F25F1C51-67E0-469E-9607-8C552626F289Q38091393-3D46084F-B0E2-4016-A021-2DCCA8033745Q38104287-95708A33-4DCB-4EDB-AA9A-D55A32C12EB6Q38106983-8A13ACE4-E019-4BF4-ACB9-D59397CCC45FQ38124066-8FFE6298-01B9-4E62-9143-3AB63EFB0F01Q38161965-82922037-BB62-4723-A0F6-FBCB37698794Q38242272-01B24021-D5CB-4481-866D-F235F163CBC4Q38569175-F891D523-B54A-472A-BA0D-AD88786F0B14Q38760822-27AA8B40-8621-4692-B169-F2E55CE6529DQ38767583-FADC763A-0BD9-48AF-920B-78AE0425FCC4Q38835119-D387D866-2D61-4627-B869-F0D45A37D99CQ38916984-F41D432F-C5AB-4225-87C5-3183525E8800
P2860
Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@ast
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@en
Postremission treatment of eld ...... te Leukemia French Association
@nl
type
label
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@ast
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@en
Postremission treatment of eld ...... te Leukemia French Association
@nl
prefLabel
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@ast
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@en
Postremission treatment of eld ...... te Leukemia French Association
@nl
P2093
P921
P1433
P1476
Postremission treatment of eld ...... Association (ALFA) 9803 trial.
@en
P2093
Cecile Pautas
Christine Terre
Claude Gardin
Claude Preudhomme
Dominique Bordessoule
Emmanuel Raffoux
Jean-Henri Bourhis
Mauricette Michallet
Nathalie Contentin
Oumedaly Reman
P304
P356
10.1182/BLOOD-2007-02-069666
P407
P577
2007-03-06T00:00:00Z